SCHEMBL903553

SCHEMBL903553

O=C(O)CCCCCOCCCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 6/20 0.83
▸ PKM P14618 2/20 0.83
▸ MEN1 O00255 1/20 0.83
▸ ABL1 P00519 1/20 0.83
▸ LMNA P02545 1/20 0.83
▸ IDE P14735 1/20 0.83
▸ MAPK1 P28482 1/20 0.83
▸ KMT2A Q03164 1/20 0.83
▸ RIN1 Q13671 1/20 0.83
▸ L3MBTL1 Q9Y468 1/20 0.83
▸ HLCS P50747 6/20 0.62
▸ FOLH1 Q04609 2/20 0.54
▸ F2 P00734 1/20 0.53
▸ PRSS1 P07477 1/20 0.53
▸ PRSS2 P07478 1/20 0.53
▸ PRSS3 P35030 1/20 0.53
▸ TPSAB1 Q15661 1/20 0.53
▸ PLCD1 P51178 1/20 0.49
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4320917 0.92 TDP1 (0.97) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL30089573 0.92 TDP1 (0.97) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL15283293 0.92 TDP1 (0.97) TDP1PKMMEN1ABL1LMNA
SCHEMBL16141190 0.92 TDP1 (0.97) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL8071606 0.92 TDP1 (0.97) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL28797762 0.92 TDP1 (0.81) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL23055065 0.91 TDP1 (1.00) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL22943835 0.91 TDP1 (1.00) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL14489489 0.91 TDP1 (1.00) TDP1PKMMEN1ABL1LMNA
Biotin SCHEMBL20547409 0.91 TDP1 (1.00) TDP1PKMMEN1ABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2013-07-25 — — US disclosed
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2013-07-25 — — US disclosed
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2013-07-25 — — US disclosed
WO-2012042123-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2012-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY BTD, FGB, F13B TDP1 4155/4885PKM 3797/4885MEN1 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback